Last reviewed · How we verify

CMVpp65-A*0201 peptide vaccine

City of Hope Medical Center · Phase 2 active Biologic

CMVpp65-A*0201 peptide vaccine is a Vaccine Biologic drug developed by City of Hope Medical Center. It is currently in Phase 2 development for Cytomegalovirus infection.

Activates cytotoxic T cells against CMV pp65 antigen

Activates cytotoxic T cells against CMV pp65 antigen Used for Cytomegalovirus infection.

At a glance

Generic nameCMVpp65-A*0201 peptide vaccine
SponsorCity of Hope Medical Center
Drug classVaccine
TargetCMV pp65 antigen
ModalityBiologic
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

This vaccine works by stimulating an immune response against the CMV pp65 antigen, which is a protein expressed by the cytomegalovirus.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about CMVpp65-A*0201 peptide vaccine

What is CMVpp65-A*0201 peptide vaccine?

CMVpp65-A*0201 peptide vaccine is a Vaccine drug developed by City of Hope Medical Center, indicated for Cytomegalovirus infection.

How does CMVpp65-A*0201 peptide vaccine work?

Activates cytotoxic T cells against CMV pp65 antigen

What is CMVpp65-A*0201 peptide vaccine used for?

CMVpp65-A*0201 peptide vaccine is indicated for Cytomegalovirus infection.

Who makes CMVpp65-A*0201 peptide vaccine?

CMVpp65-A*0201 peptide vaccine is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

What drug class is CMVpp65-A*0201 peptide vaccine in?

CMVpp65-A*0201 peptide vaccine belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is CMVpp65-A*0201 peptide vaccine in?

CMVpp65-A*0201 peptide vaccine is in Phase 2.

What are the side effects of CMVpp65-A*0201 peptide vaccine?

Common side effects of CMVpp65-A*0201 peptide vaccine include Injection site pain, Fatigue, Headache.

What does CMVpp65-A*0201 peptide vaccine target?

CMVpp65-A*0201 peptide vaccine targets CMV pp65 antigen and is a Vaccine.

Related